Find a research study

Ask your healthcare team about taking part in research

Explore the Study Finder to learn about research that is happening in the UK today. You may be able to take part.

Need help? Take a look at our information guide.

Are you a researcher currently recruiting participants in the UK? If you would like your study included on this page, please complete this online form.

Show filter options
Reset filters
Idiopathic Pulmonary Fibrosis (IPF)
Other forms of pulmonary fibrosis
Healthy volunteers
Northern Ireland
Wales
Scotland
England
Further explanation
Trial phase

There are 3 main phases of clinical trials:

  • Phase 1 is the earliest stage of research, where there is often a focus on understanding if the treatment is safe or if it causes any side effects.
  • Phase 2 still focuses on safety and side effects, but also tries to find out more about what is the best dose.
  • Phase 3 often compares the new treatment to existing treatments or lookalike medications.

As drugs or interventions move into the different phases, the number of people taking part will increase. Not all studies will make it to the later phases, especially if the intervention is not found to be safe or effective in phase 1 and 2.

Further explanation
Trial phase

There are 3 main phases of clinical trials:

  • Phase 1 is the earliest stage of research, where there is often a focus on understanding if the treatment is safe or if it causes any side effects.
  • Phase 2 still focuses on safety and side effects, but also tries to find out more about what is the best dose.
  • Phase 3 often compares the new treatment to existing treatments or lookalike medications.

As drugs or interventions move into the different phases, the number of people taking part will increase. Not all studies will make it to the later phases, especially if the intervention is not found to be safe or effective in phase 1 and 2.

Further explanation
Trial phase

There are 3 main phases of clinical trials:

  • Phase 1 is the earliest stage of research, where there is often a focus on understanding if the treatment is safe or if it causes any side effects.
  • Phase 2 still focuses on safety and side effects, but also tries to find out more about what is the best dose.
  • Phase 3 often compares the new treatment to existing treatments or lookalike medications.

As drugs or interventions move into the different phases, the number of people taking part will increase. Not all studies will make it to the later phases, especially if the intervention is not found to be safe or effective in phase 1 and 2.

Further explanation
Open-label extension

Some studies offer an extension phase of research, where people continue to receive the new drug or therapy after the initial trial has finished. The extension phase is often ‘open-label’, which means that you will know that you are receiving the active treatment .

Further explanation
Can continue on antifibrotics

Within studies, there are different requirements that someone must meet, to be able to take part. Some studies recruit people who are taking antifibrotic medications, including nintedanib or pirfenidone. However, in other studies people taking part must not be taking antifibrotic medication.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
0
 result/s

Fibroneer-ILD: Can the drug, BI 1015550, slow lung function decline?

Results available
Upcoming
Recruiting
Closed
Up to 2.5 years
participation
Up to 2.5 years
participation
Fibroneer-ILD: A clinical trial for people with PF-ILD investigating the effects of study drug BI 1015550 on lung function

People affected by pulmonary fibrosis (PF) currently have limited treatment options to slow the progression of disease. New research studies are needed to gain valuable knowledge about potentially better treatment options.

The Fibroneer trial is a randomised controlled trial, designed to see if a medicine called BI 1015550 can help people with PF-ILD. The aim is to understand if the study drug affects scarring, inflammation and slows the rate of lung function decline.

PF-ILD is a group of progressive fibrotic interstitial lung diseases, that includes diagnoses such as: fibrotic hypersensitivity pneumonitis (fHP), rheumatoid arthritis interstitial lung disease (RA-ILD), and many others.

Taking a drug
Hospital visits
Can continue on antifibrotics
England
Scotland
III
Other forms of pulmonary fibrosis

REMOTE-ILD: Can a new mobile app help for home monitoring?

Results available
Upcoming
Recruiting
Closed
12 months
participation
12 months
participation
REMOTE-ILD: A clinical trial investigating the impact of using a mobile app for home monitoring on patients’ care

Measuring patients’ lung function is an important part of pulmonary fibrosis care. However, many factors can limit regular access to monitoring, including spirometry (breathing tests). The COVID-19 pandemic has presented additional challenges, highlighting a potential role for complimentary home monitoring options for patients. Home-based spirometry and digital technology mean that patients now have the opportunity to monitor their lung function at home.

The REMOTE-ILD study is investigating the impact of using a mobile app for home monitoring on patient care.

The study aims to understand whether monitoring lung function at home is helpful for patients and clinicians in managing pulmonary fibrosis.

In this study, the impact of regularly performing breathing tests at home in addition to usual (routine) care, is being compared to patients receiving their usual care alone. Participants will be randomly allocated to one of two groups, one monitoring their lung function at home in addition to their routine care, or and one to simply continue with their routine care. 

Other research
Home-based only
Can continue on antifibrotics
England
Idiopathic Pulmonary Fibrosis (IPF)
Other forms of pulmonary fibrosis

Can inhaled pirfenidone help people with IPF?

Results available
Upcoming
Recruiting
Closed
72 weeks
participation
72 weeks
participation
ATLAS Study: investigating if inhaled pirfenidone can help people with IPF

Pirfenidone is an antifibrotic medication that is often prescribed orally for people with IPF. The drug requires a large dose to make sure that enough reaches the lungs. This can cause significant side effects including abdominal pain, diarrhoea, sensitivity to sunlight, rashes, fatigue and liver problems. As a result of this, people with IPF often don't tolerate the drug or it has a large impact on quality of life.

Researchers have remade the drug so that it can be inhaled using a nebuliser. This means that small inhaled doses of pirfenidone can directly reach the lungs.

The ATLAS study aims to find out if inhaled pirfenidone is well tolerated and as effective as the oral medication.

Taking a drug
Hospital visits
England
I
Idiopathic Pulmonary Fibrosis (IPF)

How does garadacimab affect patients with IPF?

Results available
Upcoming
Recruiting
Closed
Up to 22 weeks
participation
Up to 22 weeks
participation
A study investigating a new drug called Garadacimab for people with IPF

The study aims to see how the body responds to a drug Garadacimab and the effect it has on people with IPF.

Taking a drug
Hospital visits
England
Northern Ireland
II
Idiopathic Pulmonary Fibrosis (IPF)

Fibroneer-IPF: Can the drug, BI 1015550, slow lung function decline?

Results available
Upcoming
Recruiting
Closed
Up to 2.5 years
participation
Up to 2.5 years
participation
Fibroneer-IPF: A clinical trial for people with IPF investigating the effects of study drug BI 1015550 on lung function

People affected by pulmonary fibrosis (PF) currently have limited treatment options to slow the progression of disease. New research studies are needed to gain valuable knowledge about potentially better treatment options.

The Fibroneer trial is a randomised controlled trial, designed to see if a medicine called BI 1015550 can help people with IPF. The aim is to understand if the study drug affects scarring, inflammation and slows the rate of lung function decline.

Taking a drug
Hospital visits
Can continue on antifibrotics
England
Scotland
III
Idiopathic Pulmonary Fibrosis (IPF)

How does PF affect sexual function?

Results available
Upcoming
Recruiting
Closed
10 minute Survey
participation
10 minute Survey
participation
Online Survey about Sexual Function for People Living with Pulmonary Fibrosis

There is currently limited information and understanding about sexual function in patients with pulmonary fibrosis (PF).

This study aims to learn if sexual dysfunction is common in patients with PF.

The study will gain greater understanding about patients’ concerns and feeling around their sexual function. This knowledge will help to improve care and quality of life for patients.

Survey
Home-based only
England
Scotland
Wales
Northern Ireland
Idiopathic Pulmonary Fibrosis (IPF)
Other forms of pulmonary fibrosis

Can a new drug HZN-825 help people with IPF?

Results available
Upcoming
Recruiting
Closed
52 weeks
participation
52 weeks
participation
A trial to understand the effect of a new drug HZN-825 in people with IPF

The clinical trial is designed to see if a new drug called HZN-825, can help people with IPF. The aim is to understand how the body responds to the new drug, and if it affects lung function.

People affected by IPF currently have limited treatment options to slow the progression of disease. New research studies such as this, are needed to gain valuable knowledge about better treatment options.

Taking a drug
Hospital visits
Open-label extension
England
II
Idiopathic Pulmonary Fibrosis (IPF)

Can orvepitant reduce IPF cough?

Results available
Upcoming
Recruiting
Closed
17 weeks
participation
17 weeks
participation
IPF COMFORT: A clinical trial investigating the effects of orvepitant on IPF cough

Many patients diagnosed with idiopathic pulmonary fibrosis experience a troublesome cough.  Treatment options are limited and clinical trials investigating better options are needed.

The IPF COMFORT study is investigating whether a study drug called orvepitant can reduce the burden  of cough in people diagnosed with IPF.

The cough in IPF may be caused by the airways becoming oversensitive. The investigational drug being tested in the study may reduce this over-sensitivity.

Taking a drug
Hybrid
Can continue on antifibrotics
England
Scotland
Northern Ireland
II
Idiopathic Pulmonary Fibrosis (IPF)

British Pigeon Fanciers Genetics of ILD Register

Results available
Upcoming
Recruiting
Closed
Up to 5 years
participation
Up to 5 years
participation
British Pigeons Fancier Study: looking at the genetics of interstitial lung disease (ILD)

Genetics can play a crucial role in the development and then progression of interstitial lung disease (ILD). This area of research is not fully understood and it is not known why some people who are exposed to pigeons, develop the disease, whilst others do not.

The British Pigeons Fancier genetics of ILD study aims to find out more about the role that genetics plays in disease development of people with ILD who are regularly exposed to pigeons. This exposure is a known cause of hypersensitivity pneumonitis, which is a form of ILD.

Pigeon fanciers use their knowledge of pigeon genetics to breed winning pigeons. Researchers will use their knowledge of human genetics to investigate why some pigeon fanciers get pigeon lung. They will then compare genetic differences between pigeon fanciers with and without pigeon lung, to understand more about the disease.

Researchers would like to recruit people with regular racing pigeon exposure at national and regional pigeon fancier meetings.

Other research
Hospital visits
Can continue on antifibrotics
Scotland
England
Idiopathic Pulmonary Fibrosis (IPF)
Other forms of pulmonary fibrosis

Can computers help to predict disease progression?

Results available
Upcoming
Recruiting
Closed
12 months
participation
12 months
participation
PREDICT-ILD: A Study Looking at ILD Progression with Computer Technology

Progression of disease for people with fibrotic lung diseases, such as pulmonary fibrosis, is often unpredictable. Lung function test are part of standard care, and used to see how the disease is progressing over time. This doesn't always give a reliable picture of how things really are, as there can be difficulties when doing the tests.

High resolution computed tomography (HRCT) scans are used for diagnosis. Results are reported by trained radiologists, which can be limited by how each person interprets what they can see. A quantitative CT approach uses computer technology to analyse the HRCT results.

This study wants to understand if the new computer technology can predict and identify disease progression in fibrotic-ILD.

Other research
England
Idiopathic Pulmonary Fibrosis (IPF)
Other forms of pulmonary fibrosis

Can a nutritional support intervention help people who are malnourished?

Results available
Upcoming
Recruiting
Closed
3 months
participation
3 months
participation
DT-ILD: Specialist dietetic support for people with fibrotic interstitial lung disease who are malnourished

Malnutrition is when the someone doesn't get enough nutrients from food to meet the demands of the body. This can be due to a variety of reasons such as an increase in the energy requirements due to the lungs working harder. Or it could be due to the antifibrotic medication that can cause significant side effects, including poor appetite, diarrhoea, nausea, vomiting and weight loss.

The consequences of malnutrition can significantly impact quality of life, increase risk of infection and hospital admission, and is thought to potentially link with survival length. Very little research has been carried out to investigate how to best support people who are facing these challenges.

The DT-ILD study aims to find out if patients are willing to see a dietitian and if this can have a positive impact on their food intake.

Other research
Hybrid
Can continue on antifibrotics
England
Idiopathic Pulmonary Fibrosis (IPF)
Other forms of pulmonary fibrosis

Can a new drug, C21, slow progression of IPF?

Results available
Upcoming
Recruiting
Closed
36 weeks
participation
36 weeks
participation
AIR Trial: A study investigating a new drug, C21, in people with Idiopathic Pulmonary Fibrosis

The AIR Trial is investigating a new drug called compound 21 (C21) in people with IPF. This is a single treatment arm study, where all participants will take the drug.

Alveolar Epithelial Type II (AT2) cells, play a vital role in maintaining and repairing healthy lung tissue. People with IPF may have fewer of these AT2 cells, or the cells may not function correctly, which can promote scarring of the lungs. The new drug can attach to the surface of these cells and help to restore their normal function within the lungs.

The aim of the AIR Trial is to see if C21 can stabilise lung function in people with IPF and slow progression of the condition.

Taking a drug
Hospital visits
England
II
Idiopathic Pulmonary Fibrosis (IPF)

Can financial incentive increase pulmonary rehabilitation participation?

Results available
Upcoming
Recruiting
Closed
participation
participation
Co-design of a financial incentive to increase pulmonary rehabilitation in people with chronic respiratory disease

Pulmonary rehabilitation is an exercise and education program that is recommended for people with certain chronic respiratory diseases, including pulmonary fibrosis.

Pulmonary rehabilitation classes often run over several weeks or months and can help patients to manage symptoms and cope with the effects of breathlessness on daily living activities. However, participation and completion of pulmonary rehabilitation often faces many different barriers.

The aim of this study is to design a financial incentive scheme to improve pulmonary rehabilitation referral, uptake and completion among people with chronic respiratory conditions and to design a study to investigate this scheme works.

Other research
Home-based only
Can continue on antifibrotics
England
Scotland
Wales
Northern Ireland
Idiopathic Pulmonary Fibrosis (IPF)
Other forms of pulmonary fibrosis
No match for these filter settings

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators. You may still be able to take part if studies aren't local to you. Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email research@actionpf.org. You may also request for a study to be added.

This page is under development. We welcome your feedback! Please email research@actionpf.org.

Are you a researcher currently recruiting participants in the UK? If you would like your study included on this page, please complete this
online form.

Can't find anything that interests you?
Check back soon as we regularly update these pages.